Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2011. The report details a specific share repurchase transaction executed on June 9, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to a share buyback.
- Shares Purchased: 800,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,302.5 pence per share; lowest price paid was 1,294 pence per share.
- Treasury Shares: Following cancellation, the Company holds 499,174,284 shares in Treasury.
- Treasury Ownership: Represents 8.83% of total issued share capital and 9.69% of total voting rights.
- Shares in Issue: 5,153,579,548 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the Company's issued share capital through the purchase and cancellation of 800,000 shares. This transaction increased the proportion of Treasury shares held by the Company relative to total voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,153,579,548) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (499,174,284) and its impact on voting rights (9.69%).
- Review the Annual General Meeting minutes from May 5, 2011, to confirm the scope of the share repurchase authority utilized.